0000000000445046

AUTHOR

M. Klausmann

showing 2 related works from this author

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk …

1998

To improve the complete remission (CR) rate and to prolong CR duration in patients with advanced MDS, AML evolving from MDS, and secondary AML, a phase-III trial of aggressive chemotherapy followed by G-CSF was initiated in January 1992. Pts. achieving a CR were randomized to receive either high-dose or low-dose IL-2 to evaluate the potential of this cytokine to eliminate residual leukemic cells and to prolong the CR duration.

Interleukin 2Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMyeloid leukemiaImmunotherapyCytokinehemic and lymphatic diseasesInternal medicinemedicineIdarubicinbusinessAmsacrineARA-C/VP-16medicine.drug
researchProduct

Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes

1990

Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is only suitable for a very small proportion of patients. Thus, there is a need for new therapeutic alternatives.

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryCellular differentiationmedicine.medical_treatmentMyelodysplastic syndromesmedicine.diseaseLeukemiaGranulocyte macrophage colony-stimulating factorCytokineInternal medicinePrecursor cellImmunologyCytarabineMedicinebusinessmedicine.drug
researchProduct